Sulodexide, traded as Aterina, is a highly purified mixture of glycosaminoglycans composed of heparan sulfate (80%) and dermatan sulfate (20%). The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin.

Sulodexide is a drug used to treat chronic venous ulcers in the legs. Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH). The next evolution of DrugBank is here. Designed for scientists, driven by AI, and powered by real-time insights. This is drug intelligence, redefined.

Sulodexide facilitates the healing of venous ulcers and is frequently used in patients with CVD without ulcer. This review assessed the efficacy and safety of sulodexide for treatment of signs and symptoms of lower extremity CVD.

Sulodexide (SDX), a sulfated polysaccharide complex extracted from porcine intestinal mucosa, is a blend of two glycosaminoglycan (GAG) entities, namely a fast-moving heparin (HP) fraction and a dermatan sulfate (DS; 20%) component.

2025年1月7日 · Sulodexida is a drug used to treat chronic venous ulcers in the legs. Sulodexida has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion.

2015年9月25日 · Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known.

Sulodexide (Vessel; Alfasigma, Bologna, Italy) is a naturally occurring glycosaminoglycan that is purified from porcine intestinal mucosa. It is prescribed to help manage chronic venous disease (CVeD) and to prevent recurrent venous thromboembolism (VTE) in parts of Europe, South America, and Asia.

Sulodexide has emerged as a potential therapeutic option for the management of chronic venous insufficiency, including venous ulceration, and the prevention of recurrent venous thromboembolism, with a low rate of major bleeding complications. Sulodexide's pleiotropic vascular effects may facilitate the management of common venous disorders.

Sulodexide is composed of glycosaminoglycan that includes a mixture of fast-moving heparin and dermatan sulfate. It exerts its anticoagulant and antithrombotic action through interactions with both AT and HCII.

* 1 mg de Sulodexida presenta una actividad ≥ a 10 LRU, lo que equivale a 250 LRU. INDICACIONES TERAPÉUTICAS: Enfermedad venosa crónica, incluyendo úlceras venosas de las piernas y síndrome postrombótico. Prevención de trombosis venosa recurrente. Previene o retarda la nefropatía secundaria a diabetes mellitus.